Rankings
▼
Calendar
CTMX Q2 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$25M
+1.6% YoY
Gross Profit
$25M
100.0% margin
Operating Income
-$8M
-33.7% margin
Net Income
-$7M
-26.0% margin
EPS (Diluted)
$-0.08
QoQ Revenue Growth
-39.4%
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$20M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$159M
Total Liabilities
$190M
Stockholders' Equity
-$31M
Cash & Equivalents
$43M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$25M
$25M
+1.6%
Gross Profit
$25M
$23M
+8.3%
Operating Income
-$8M
-$3M
-152.4%
Net Income
-$7M
-$1M
-501.1%
← FY 2024
All Quarters
Q3 2024 →